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ABSTRACT
Objective: Diabetes mellitus is a set of metabolic disease in which there is increased blood sugar level over a long period. The objective of the study 
is in silico design of quinoxaline bearing thiazolidinone derivatives as peroxisome proliferator-activated receptor gamma (PPARγagonist in diabetes 
mellitus.
Methods: In silico design of proposed derivatives was conducted by ACD Lab ChemSketch 12.0 and derivatives obeying Lipinski’s rule of five were 
selected for docking studies. Docking was carried out using AutoDock Vina software.
Results: Molinspiration results revealed that the designed derivatives had physical and chemical properties meant for an orally available drug. Based 
on the docking results derivatives, QNT1 and QNT2 exhibited high docking score which indicates that these derivatives possess high-affinity and high 
polar interaction toward protein 1PRG (ligand-binding domain of human peroxisome proliferator-activated receptor gamma).
Conclusion: The designed quinoxaline bearing thiazolidinone derivatives were found to possess good binding affinity and good interaction in the 
binding pocket of target 1PRG, so these derivatives are expected to exhibit good antidiabetic property with minimal side effects.
Keywords: Diabetes mellitus, PPARγ agonist, Docking, AutoDock Vina, Pioglitazone.
INTRODUCTION
Diabetes mellitus is a group of chronic metabolic disorders of multiple 
etiologies characterized by hyperglycemia with disturbances of 
carbohydrate, fat, and protein metabolism resulting from relative or 
an absolute lack in insulin. Diabetes mellitus is of three types: Type 1 
diabetes mellitus – an autoimmune disease in which the body’s own 
immune system attacks the pancreas, making it unable to produce 
insulin, type 2 diabetes mellitus – in which a resistance to the effects 
of insulin or a defect in insulin secretion may be seen, and type 3 – 
gestational diabetes – is a condition in which blood sugar levels become 
high during pregnancy [1].
Currently used antidiabetic drugs include biguanides such as metformin, 
sulfonylureas such as glimepiride and glipizide, meglitinides such as 
repaglinide and nateglinide, and thiazolidinones such as pioglitazone 
and rosiglitazone [2-5]. Side effects of these drugs include kidney 
complications, weight gain, risk of liver disease, gas bloating, diarrhea, 
and anemia.
Quinoxaline derivatives constitute an important class of heterocycles in 
drug discovery. They are clinically effective as antibacterial, antifungal, 
anti-inflammatory, anticancer, antitubercular, and antineoplastic. It also 
shows hypoglycemic and antiglaucoma activity [6]. Thiazolidinones 
are an important scaffold with antidiabetic, anticancer, antibacterial, 
antiviral, and antioxidant properties [7].
PPARγ is a well-known target for diabetes and thiazolidinones which 
include rosiglitazone and pioglitazone, acts through PPARγ. PPARγ 
helps in glucose and lipid uptake, kindles glucose oxidation, decreases 
free fatty acid level, and improves insulin resistance. They are highly 
present in adipose tissues that play a significant role on insulin 
resistance, cell differentiation, and energy metabolism [8-10]. All 
the PPARs have similar structures and mechanism of action. Based 
on structure-function relationship, PPARs can be divided into three 
domains; (a) ligand binding domain which consists of 12 alpha helixes 
with a hydrophobic pocket, where the ligand binds, (b) trans-activating 
domain which is essential for transcriptional activation, and (c) DNA-
binding domain which interacts with specific PPAR response elements 
in the promoter region of the target genes [11-14].
METHODS
ACD Lab ChemSketch 12.00 and molinspiration
It used for drawing chemical structures, 3D optimizing and calculating 
various physicochemical properties of the proposed derivatives. In 
this study, about 15 compounds were designed and from this, five 
derivatives possessed druglikeness properties and obeyed Lipinski rule 
of five. These five derivatives were selected for docking studies.
Protein data bank (PDB)
PDB is the single worldwide repository of information about the 3D 
structures of large biological molecules, including proteins and nucleic 
acid. Under Protien data bank: PDB ID is the 4-character unique 
identifier of every entry in the PDB. In this study, the selected protein is 
PPARγ shown in Fig. 1 and the PDB ID is 1PRG (ligand-binding domain 
of peroxisome proliferator-activated receptor gamma).
Molecular docking
Docking is the prediction of affinity and the activity of designed 
derivatives to the suitable protein targets. AutoDock Vina is an open 
source program for doing molecular docking. PyMOL was used for 
protein preparation and visualization. PyRx was used for docking [15].
Protein preparation
Structure which was taken from the PDB database could not fit as 
such for docking studies. Under Protein preparation: docking studies, 
because the structure consist of water molecule (HOH), detergents 
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(DSN), small molecules, cofactors and metal ions. Therefore, the PDB 
structure should be converted into suitable form for docking by addition 
of command “remove<>resn<>molecules” (HOH,DSN). Hydrogen atoms 
should be added to the protein structure.
Ligand preparation
The structures of derivatives were drawn using ACD Lab ChemSketch 
12.0 and converted into 3D PDB format using Corina online software.
Docking by AutoDock Vina
Docking was performed using PyRx where both the protein and the 
derivative were loaded into the navigation pane. Then, the protein was 
converted into macromolecule whereas the derivative was converted 
into ligand molecule. After the preparation of protein and ligand, 
click the AutoDock Vina wizard start button and adjust the grid size. 
The accuracy of the result depends on the number of exhaustiveness. 
Exhaustiveness is the number of times the ligand must be docked 
against the protein in different positions. After the completion of 
process, the result was displayed in a table. The binding affinity of the 
protein is indicated in Kcal/mol [16-18].
Visualization and analysis
The PyMOL molecular graphics system was used to analyze the hydrogen 
bond, hydrophobic bond and pi-pi interactions. PyMOL can produce high-
quality 3D images of small molecules and macromolecules such as proteins.
RESULTS
Computer-assisted drug design (CADD) approach has contributed to 
the successful discovery of novel quinoxaline bearing thiazolidinone 
derivatives as antidiabetic agents. A series of structurally related 
compounds were designed. Those compounds obeying rule of five were 
selected for docking studies and they are illustrated in Table 1. The 
molecular docking analysis of the selected derivative with the receptor 
PPARγ(1PRG – ligand-binding domain of peroxisome proliferator-
activated receptor gamma) has been performed. Schematic 3D 
representation of derivative with receptor PPARγ(1PRG) was visualized 
and shown in Fig. 2. The docking score of derivatives and the standard 
(pioglitazone) with the 1PRG is given in Table 2. QNT1 shows hydrogen 
bond interaction with TYR-743, QNT2 with THR-731, QNT3 with LYS-
728, QNT4 with PHE-650, QNT5 with LYZ-728, and the thiazolidinone 
ring present in the pioglitazone display hydrogen bond interaction with 
PHE-360 and LEU-246.
DISCUSSION
Designed quinoxaline bearing thiazolidinone possessing druglikeness 
property and obeying Lipinski rule of five were selected for docking 
studies. The values of the parameters of Lipinski rule of five are shown 
Table 2: Docking score of derivatives and standard 
(pioglitazone) with protein 1PRG (ligand binding domain of 
peroxisome proliferator-activated receptor gamma)
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Table 1: Structure and molecular descriptors of derivatives and standard (pioglitazone)
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Fig. 1: Structure of PPARγ
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in Table 1. Since there was no violation in rule of five, these derivatives 
are found to possess physical and chemical property to be orally 
bioavailable. Docking analysis reveals that these derivatives exhibit 
good hydrogen bond interaction with protein 1 PRG. Docking score is 
shown in Table 2 and docking images of five derivatives and standard 
are shown in Fig. 2. Hence, these derivatives are expected to have good 
in vivo and in vitro antidiabetic activity.
CONCLUSION
The designed quinoxaline bearing thiazolidinone derivatives are found 
to have good interaction in the binding pocket of target 1 PRG so these 
compounds are expected to possess good antidiabetic property with 
minimum side effects.
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Fig. 2: Docked images of derivatives and standard (pioglitazone) with protein 1PRG (ligand-binding domain of peroxisome proliferator-
activated receptor gamma)
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